Skip to main content

Advertisement

SpringerLink
Log in

Should Anti-EGFR Agents Be Used in Right-Sided RAS Wild-type Advanced Colorectal Cancer?

  • Systemic Therapies in Colorectal Cancer (SM Kazmi, Section Editor)
  • Published:
Current Colorectal Cancer Reports

Abstract

Purpose of Review

Colorectal cancer is the third most common cancer worldwide with a high mortality rate at the advanced stages of the disease. Treatment options are dependent on the stage of the disease, patients’ performance status, and the specific molecular makeup of the tumor. Adding an anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb) to conventional chemotherapy in molecularly selected patients (i.e., RAS wild-type) leads to a survival advantage. We aim to review the latest evidence on the influence of primary tumor location (PTL) on treatment response to chemotherapy combined with an anti-EGFR in patients with metastatic colorectal cancer (mCRC).

Recent Findings

Colon cancer arising on the left side versus the right side of the colon portrays different outcomes, emerging PTL as an important characteristic in understanding the outcomes for patients with colorectal cancer. Patients with right-sided tumors have a worse prognosis than those with left-sided tumors. Primary tumor location may also be predictive of treatment benefit from targeted therapy with an anti-EGFR or anti-VEGF in the treatment of RAS wild-type mCRC. Although no benefit in overall survival (OS) has been demonstrated, available data up to now can endorse the use of an anti-EGFR in right-sided RAS wild-type advanced colorectal cancer if the therapy goal is tumor shrinkage (given the higher objective response rate). However, the majority of data on PTL has been obtained through retrospective analysis of clinical trials where PTL was neither part of the stratification nor pre-planned subgroup analysis, rendering it susceptible to recall bias.

Summary

There is a great necessity to improve our understanding of the molecular and histological variability in left versus right-sided colon cancer and its impact on future targeted therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.

    Article  Google Scholar 

  2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.

    Article  CAS  Google Scholar 

  3. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386e422.

    Google Scholar 

  4. Venook A, Niedzwiecki D, Innocenti F, et al. Impact of primary tumor location on overall survival and progression-free survival in patients with metastatic colorectal cancer: analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34. (suppl, abstr 3504:3504.

  5. Karim S, Brennan K, Nanji S, Berry SR, Booth CM. Association between prognosis and tumor laterality in early-stage colon cancer. JAMA Oncol. 2017;3(10):1386–92.

    Article  PubMed  PubMed Central  Google Scholar 

  6. • Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113(10):779–88. First proposed the concept that proximal and distal colons were 2 different entities.

  7. Missiaglia E, Jacobs B, D’ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25:1995–2001.

    Article  CAS  Google Scholar 

  8. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26(1):13–21.

    Article  CAS  PubMed  Google Scholar 

  9. Tejpar S, Stintzing S, Ciardiello F, Tabernero J, van Cutsem E, Beier F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3(2):194–201.

    Article  PubMed  Google Scholar 

  10. Brule SY, Jonker DJ, Karapetis CS, et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer. 2015;51:1405–14.

    Article  CAS  PubMed  Google Scholar 

  11. Wang F, Bai L, Liu TS, Yu YY, He MM, Liu KY, et al. Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab. Chin J Cancer. 2015;34(9):384–93.

    CAS  PubMed  Google Scholar 

  12. Boeckx N, Koukakis R, Op de Beeck K, et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol. 2017;28:1862–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, et al. Prognostic and predictive value of primary tumor side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28:1713–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomized, open-label phase 3 trial. Lancet Oncol. 2014;15:1065–75.

    Article  CAS  PubMed  Google Scholar 

  15. Seligmann JF, Elliott F, Richman SD, et al. Primary tumour location (PTL) as a prognostic and predictive factor in advanced colorectal cancer: data from 2075 patients in randomised trials. Ann Oncol. 2014;25(suppl_4):iv167–209.

    Google Scholar 

  16. Moretto R, Cremolini C, Rossini D, Pietrantonio F, Battaglin F, Mennitto A, et al. Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. Oncologist. 2016;21(8):988–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87–98.

    Article  Google Scholar 

  18. •• Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3(2):211–9. Largest data set available on influence primary tumor location on overall survival.

  19. Chang GJ, Gonen M. Prognostic and predictive ability of tumor sidedness: another vexing difference between localized and advanced colon cancer. JAMA Oncol. 2017;3(10):1314–5.

    Article  PubMed  Google Scholar 

  20. Lee GH, Malietzis G, Askari A, Bernardo D, al-Hassi HO, Clark SK. Is right-sided colon cancer different to left-sided colorectal cancer? A systematic review. Eur J Surg Oncol. 2015;41:300–8.

    Article  CAS  PubMed  Google Scholar 

  21. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011–9.

    Article  CAS  PubMed  Google Scholar 

  22. Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34.

    Article  CAS  PubMed  Google Scholar 

  23. Dienstmann R, Guinney J, Delorenzi M, de Reynies A, Roepman P, Sadanandam A, et al. Colorectal cancer subtyping consortium (CRCSC) identification of a consensus of molecular subtypes. J Clin Oncol. 2014;32(15_suppl):3511.

    Article  Google Scholar 

  24. •• Maus MKH, Hanna DL, Stephens CL, et al. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics J. 2015;15(4):354–62. Highlighting the importance of specific genetic features and expression profiles according to primary tumor location. Important in future research.

  25. Ulivi P, Scarpi E, Chiadini E, Marisi G, Valgiusti M, Capelli L, et al. Right- vs. left-sided metastatic colorectal cancer: difference in tumor biology and bevacizumab efficacy. Int J Mol Sci. 2017;18(6):1240.

    Article  CAS  PubMed Central  Google Scholar 

  26. Yaeger R, Chatila WK, Lipsyc MD. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell. 2018;33:125–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departement of Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium

    Lars Triest, C. Debeuckelaere, T. Vandamme, B. Van Den Heuvel, J. Van Den Brande, K. Papadimitriou, M. Rasschaert, H. Prenen & M. Peeters

Authors
  1. Lars Triest
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Debeuckelaere
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Vandamme
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Van Den Heuvel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Van Den Brande
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. Papadimitriou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Rasschaert
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Prenen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Peeters
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lars Triest.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Systemic Therapies in Colorectal Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Triest, L., Debeuckelaere, C., Vandamme, T. et al. Should Anti-EGFR Agents Be Used in Right-Sided RAS Wild-type Advanced Colorectal Cancer?. Curr Colorectal Cancer Rep 15, 130–134 (2019). https://doi.org/10.1007/s11888-019-00439-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-019-00439-x

Keywords

Search

Navigation